Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

BACKGROUND: Severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused a devastating worldwide pandemic. Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2, but clinical data supporting HCQ for coronavirus disease 2019 (COVID-19) are limited. METHODS: This was a retrospective coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Satlin, Michael J., Goyal, Parag, Magleby, Reed, Maldarelli, Grace A., Pham, Khanh, Kondo, Maiko, Schenck, Edward J., Rennert, Hanna, Westblade, Lars F., Choi, Justin J., Safford, Monika M., Gulick, Roy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377460/
https://www.ncbi.nlm.nih.gov/pubmed/32701969
http://dx.doi.org/10.1371/journal.pone.0236778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377460/
https://www.ncbi.nlm.nih.gov/pubmed/32701969
http://dx.doi.org/10.1371/journal.pone.0236778

Ejemplares similares